Infinium Pharmachem Releases Audited Financial Results for FY 2025-26; Net Profit Reported
Infinium Pharmachem Limited has released its audited financial results for the year ended March 31, 2026. The company’s Board of Directors considered and approved the Annual Audited Standalone and Consolidated Financial Statements for the fiscal year.The Company reported a Total Income of 15785.65 Rs. in Lacs for the year ended March 31, 2026 (Standalone). In the consolidated results, revenue from operations stood at 19176.96 Rs. in Lacs. The net profit before tax for the company was reported as 1784.04 Rs. in Lacs.
Board Meeting Outcomes and Governance
During the Board meeting held on May 29, 2026, the Directors reviewed several material items regarding corporate operations and financial integrity.Key approvals included:
- Approval of the Audited Standalone Financial Statements along with the draft Auditors' Report for FY ended March 31, 2026.
- Approval of the Audited Consolidated Financial Statements for the same period.
- The Board took note of the Statement of Deviation and variation in the utilization of funds raised through IPO and Preferential issue for the half year ended March 31, 2026, confirming that there was no deviation in fund utilization.
Furthermore, the company’s governance matters included taking note of the CSR contribution made during the FY 2025-26 and noting the temporary closure of operations following a GPCB order and its subsequent revocation. The Board also approved the criteria for granting omnibus approval for related party transactions for the financial year 2026-27.
Financial Performance Highlights
The management's performance in terms of profitability and cash flow is detailed across both standalone and consolidated reports.Financial Snapshot (in Rs. Lacs)
| Metric | Standalone (FY 2026) | Consolidated (FY 2026) |
|---|---|---|
| Total Income / Revenue from Operations | 15785.65 | 19176.96 |
| Profit Before Taxes | 1351.46 | 1784.04 |
| Net Profit for the period (PAT) | 351.46 | Data not specified in summary table |
| Cash Flow from Operations (CFO) | 2096.21 | 1513.94 |
Audit and Review Status
The company's statutory auditors, Ashok Rajpara & Co., issued an Unmodified Opinion on the Audited Standalone and Consolidated financial results for the period ended March 31, 2026.One foreign subsidiary included in the consolidated statements was noted to have total assets of Rs. 1411.64 Lakhs as at March 31, 2026, with a net profit after tax of Rs. 386.46 Lakhs for the year ended on that date.
The board members also confirmed their responsibility for overseeing the company’s financial reporting process and ensuring adherence to accounting principles generally accepted in India.
INFINIUM Stock Price Movement
As of 2:34 PM, shares of Infinium Pharmachem Limited are slipping by 0.47% in live trading, currently at ₹213 following a drop of ₹1.00. The stock's intraday range remains wide, with traded volume reaching 4,000 and the security hitting its daily low at ₹213.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.